K2 Oncology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
K2 Oncology - overview
Established
2016
Location
Beijing, -, China
Primary Industry
Pharmaceuticals
About
Founded in 2016 and based in Beijing, China, K2 Oncology is a a medical technology that focuses on the development of anti-tumor drugs. The company has an R&D center of 800 square meters, a clinical medical laboratory of 1300 square meters and a GMP-level cell culture production workshop. Zhijian Sun, founder and CEO of the company, was a senior researcher at BeiGene and the head of in vitro pharmacology of the innovative drug zanubrutinib. The company has iaCyte organoid technology platform, human cell stem cell culture technology platform PDOX technology platform and organoid culture medium kit, etc.
OrganoProTM Organoid Medium Kit is suitable for organoid culture of gastric cancer, ovarian cancer and breast cancer.
Current Investors
FOF Capital, Tengye Ventures, Detong Capital
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.k2oncology.cn
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.